 The companys key product candidate is FB-401, a topical live biotherapeutic, with three therapeutic strains of commensal gram-negative bacteria Roseomonas mucosa. FB-401 is being developed in mild to moderate atopic dermatitis and has FDA Fast track designation based on Phase 1a2 data. 